Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

Experimental Hematology

Volumn 31, Issue 4, 2003, Pages 290-299

  Egrie, Joan C ^a   Dwyer, Erik ^a   Browne, Jeffrey K ^a   Hitz, Anna ^a   Lykos, Michele A ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ARTICLE; CARBOHYDRATE ANALYSIS; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; HEMATOCRIT; HUMAN; HUMAN CELL; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

CANIS FAMILIARIS; TRIXIS;

EID: 0037384789     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00006-7     Document Type: Article

References (42)

1. Krantz S.B. Erythropoietin. Blood. 77:1991;419-434.
2. Lacombe C., Mayeux P. Biology of erythropoietin. Haematologica. 83:1998;724-732.
3. D'Andrea A.D., Lodish H.F., Wong G.G. Expression cloning of the murine erythropoietin receptor. Cell. 57:1989;277-285.
4. Lodish H.F., Hilton D.J., Klingmuller U., Watowich S.S., Wu H. The erythropoietin receptor. biogenesis, dimerization, and intracellular signal transduction Cold Spring Harb Symp Quant Biol. 60:1995;93-104.
5. Constantinescu S.N., Ghaffari S., Lodish H.F. The erythropoietin receptor. Structure, activation and intracellular signal transduction Trends Endocrinol Metab. 10:1999;18-23.
6. Winearls C.G., Oliver D.O., Pippard M.J., Reid C., Downing M.R., Cotes P.M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 2:1986;1175-1178.
7. Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 316:1987;73-78.
8. Eschbach J.W., Abdulhadi M.H., Browne J.K.et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 111:1989;992-1000.
9. Markham A., Bryson H.M. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs. 49:1995;232-254.
10. Cazzola M., Mercuriali F., Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 89:1997;4248-4267.
11. Sowade B., Sowade O., Mocks J., Franke W., Warnke H. The safety of treatment with recombinant human erythropoietin in clinical use. A review of controlled studies Int J Mol Med. 1:1998;303-314.
12. nd ed:1985;Appleton-Century-Crofts, Norwalk (CT).
13. th ed:1996;29-41 McGraw-Hill, New York.
14. Egrie JC, Grant JR, Gillies DK, Aoki KH, Strickland TW. The role of carbohydrate on the biological activity of erythropoietin [abstract]. Glycoconjugate J. 1993;10:263(Abstract S7.7).
15. Egrie J.C., Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 84(suppl 1):2001;3-10.
16. Browne J.K., Cohen A.M., Egrie J.C.et al. Erythropoietin. gene cloning, protein structure, and biological properties Cold Spring Harb Symp Quant Biol. 51:1986;693-702.
17. Egrie J.C., Strickland T.W., Lane J.et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology. 172:1986;213-224.
18. Lai P.H., Everett R., Wang F.F., Arakawa T., Goldwasser E. Structural characterization of human erythropoietin. J Biol Chem. 261:1986;3116-3121.
19. Recny M.A., Scoble H.A., Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem. 262:1987;17156-17163.
20. Bondurant M.C., Koury M.J. Anemia induces the accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol. 6:1986;2731-2733.
21. Sasaki H., Bothner B., Dell A., Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem. 262:1987;12059-12076.
22. Sasaki H., Ochi N., Dell A., Fukuda M. Site-specific glycosylation of human recombinant erythropoietin. analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry Biochemistry. 27:1988;8618-8626.
23. Takeuchi M., Takasaki S., Miyazaki H.et al. Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J Biol Chem. 263:1988;3657-3663.
24. Tsuda E., Goto M., Murakami A.et al. Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins. Biochemistry. 27:1988;5646-5654.
25. Inoue N., Takeuchi M., Asano K., Shimizu R., Takasaki S., Kobata A. Structures of mucin-type sugar chains on the erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. Arch Biochem Biophys. 301:1993;375-378.
26. Hokke C.H., Bergwerff A.A., Van Dedem G.W.K., Kamerling J.P., Vliegenthart F.G. Structural analysis of the sialylated N- and O-linked carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. Eur J Biochem. 228:1995;981-1008.
27. Lowry P.H., Keighley G., Borsook H. Inactivation of erythropoietin by neuraminidase and mild substitution reactions. Nature. 185:1960;102-103.
28. Lukowsky W.A., Painter R.H. Studies on the role of sialic acid in the physical and biological properties of erythropoietin. Can J Biochem. 50:1972;909-917.
29. Goldwasser E., Kung C.K., Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem. 249:1974;4202-4206.
30. Dordal M.S., Wang F.F., Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology. 116:1985;2293-2299.
31. Fukuda M.N., Sasaki H., Lopez L., Fukuda M. Survival of recombinant erythropoietin in the circulation. the role of carbohydrates Blood. 73:1989;84-89.
32. Spivak J.L., Hogans B.B. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood. 73:1989;90-99.
33. Tsuda E., Kawanishi G., Ueda M., Masuda S., Sasaki R. The role of carbohydrate in recombinant human erythropoietin. Eur J Biochem. 188:1990;405-411.
34. Higuchi M., Oh-eda M., Kuboniwa H., Tomonoh K., Shimonaka Y., Ochi N. Role of sugar chains in the expression of the biological activity of human erythropoietin. J Biol Chem. 267:1992;7703-7709.
35. Elliott SG, Lorenzini T, Strickland T, Delorme E, Egrie JC. Rational design of novel erythropoiesis stimulating protein (ARANESP): a super-sialated molecule with increased biological activity [abstract]. Blood. 2000;96:82(Abstract 352).
36. 131I-labeled human growth hormone of high specific activity. Biochem J. 89:1963;493-502.
37. Egrie J.C., Cotes P.M., Lane J., Gaines Das R.E., Tam R.C. Development of radioimmunoassay for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J Immunol Methods. 99:1987;235-241.
38. Laemmli U.K. Cleavage of structural proteins during assembly of the head of the bacteriophage T4. Nature. 227:1970;680-685.
39. nd ed. New York.
40. Broudy V.C., Lin N., Egrie J.et al. Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide. Proc Natl Acad Sci U S A. 85:1988;6513-6517.
41. nd ed:1987;Springer-Verlag, New York.
42. Macdougall I.C., Gray S.J., Elston O.et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 10:1999;2392-2395.